

Haematologica
HAEMATOL/2018/192088
Version 4

Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure

Yang Y. Ding, Julie W. Stern, Tracey F. Jubelirer, Gerald B. Wertheim, Fumin Li, Fengqi Chang, Zhaohui Gu, Charles G. Mullighan, Yong Li, Richard C. Harvey, I-Ming Chen, Cheryl L. Willman, Stephen P. Hunger, Marilyn M. Li, and Sarah K. Tasian

Disclosures: 1. Ruxolitinib for preclinical studies was provided by Incyte Corporation via approved materials transfer agreement to the Children's Hospital of Philadelphia (SKT). 2. SPH has received honoraria from Amgen, Jazz Pharmaceuticals, and Erytech and consulting fees from Novartis. SKT receives research funding from Gilead Sciences and Incyte Corporation for other studies. The remaining authors declare no competing interests. 3. RCH, I-MC, and CLW are co-inventors on US Patent No. 8 568 974 B2 'Identification of novel subgroups of high risk pediatric precursor-B acute lymphoblastic leukemia, outcome correlations and diagnostic and therapeutic methods related to same.' This technology has not been licensed, and the inventors have waived all patent rights.

Contributions: YYD analysed data and wrote the manuscript. JWS and TFJ provided clinical care of the patient and analysed data. GBW, FL, FC, ZG, CGM, RCH, I-MC, YL, CLW, SPH, and MML performed research studies and/or analysed data. SKT provided clinical care of the patient, designed and directed the project, analysed data, and wrote the manuscript.